



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2013

Entry of influenza A virus: host factors and antiviral targets

Edinger, T O ; Pohl, M O ; Stertz, S

Abstract: Influenza virus is a major human pathogen that causes annual epidemics and occasional pandemics. Moreover, the virus causes outbreaks in poultry and other animals, such as pigs, requiring costly and laborious countermeasures. Therefore, influenza virus has a substantial impact on health and the global economy. Here, we review entry of this important pathogen into target cells, an essential process by which viral genomes are delivered from extracellular virions to sites of transcription/replication in the cell nucleus. We summarize current knowledge on the interaction of influenza viruses with their receptor, sialic acid, and highlight the ongoing search for additional receptors. We describe receptor-mediated endocytosis and the recently discovered macropinocytosis as alternative virus uptake pathways, and illustrate the subsequent endosomal trafficking of the virus with advanced live microscopy techniques. Release of virus from the endosome and import of the viral ribonucleoproteins into the host cell nucleus are also outlined. Although a focus has been on viral protein function during entry, recent studies have revealed exciting information on cellular factors required for influenza virus entry. We highlight these, and discuss established entry inhibitors targeting viral and host factors, as well as the latest prospects for designing novel ‘anti-entry’ compounds. New entry inhibitors are of particular importance for current efforts to develop the next generation of anti-influenza drugs – entry is the first essential step of virus replication and is an ideal target to block infection efficiently.

DOI: <https://doi.org/10.1099/vir.0.059477-0>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-101534>

Journal Article

Accepted Version

Originally published at:

Edinger, T O; Pohl, M O; Stertz, S (2013). Entry of influenza A virus: host factors and antiviral targets. *Journal of General Virology*, 95:263-277.

DOI: <https://doi.org/10.1099/vir.0.059477-0>

Entry of influenza A virus – host factors and antiviral targets

Running title: Entry of influenza A virus

Category: review article

Thomas O. Edinger [#], Marie-Theres O. Pohl [#] and Silke Stertz ^{*}

Institute of Medical Virology, University of Zurich, 8057 Zurich, Switzerland

[#] equal author contribution

^{*} corresponding author: Silke Stertz

e-mail: stertz.silke@virology.uzh.ch

phone: +41 44 634 2899

fax: +41 44 634 4967

word counts: abstract: 233 words

main text: 7149 words

number of figures: 3

number of tables: 2

1 **SUMMARY**

2 Influenza virus is a major human pathogen that causes annual epidemics and
3 occasional pandemics. Moreover, the virus causes outbreaks in poultry and other
4 animals, such as pigs, requiring costly and laborious countermeasures. Therefore,
5 influenza virus has a substantial impact on health and the global economy. Here, we
6 review entry of this important pathogen into target cells, an essential process by
7 which viral genomes are delivered from extracellular virions to sites of
8 transcription/replication in the cell nucleus. We summarize current knowledge on the
9 interaction of influenza viruses with their receptor, sialic acid, and highlight the
10 ongoing search for additional receptors. We describe receptor-mediated endocytosis
11 and the recently discovered macropinocytosis as alternative virus uptake pathways,
12 and illustrate the subsequent endosomal trafficking of the virus with advanced live
13 microscopy techniques. Release of virus from the endosome and import of the viral
14 ribonucleoproteins into the host cell nucleus are also outlined. Although a focus has
15 been on viral protein function during entry, recent studies have revealed exciting
16 information on cellular factors required for influenza virus entry. We highlight these,
17 and discuss both established entry inhibitors targeting viral and host factors, as well
18 as the latest prospects for designing novel 'anti-entry' compounds. New entry
19 inhibitors are of particular importance for current efforts to develop the next
20 generation of anti-influenza drugs – entry is the first essential step of virus replication
21 and is an ideal target to block infection efficiently.

22 INTRODUCTION

23 Influenza A virus (IAV), the causative agent of influenza, is a large burden to the
24 economy and public health world-wide. With waterfowl as the primary reservoir the
25 virus is able to infect a wide variety of birds and mammals, including humans. Due to
26 this trait, zoonotic spillovers occur occasionally and can lead to pandemics with
27 severe consequences for the human population. The swine origin H1N1 virus from
28 the 2009 pandemic and the H5N1 and H7N9 avian influenza viruses are recent
29 examples of animal viruses that acquired the potential to infect and cause disease in
30 humans. A detailed understanding of the viral lifecycle is required to assess or
31 predict the impact of circulating as well as newly emerging viruses but also to
32 develop anti-influenza drugs. The entry process of the virus represents a favorable
33 target for drug development since inhibition of this first step of virus infection should
34 result in an efficient block of virus propagation. One possibility is to target viral
35 proteins essential for entry, e.g. the receptor-binding protein hemagglutinin (HA). An
36 alternative approach is to target cellular proteins required for entry. While in the latter
37 case toxicity could represent an obstacle this strategy would offer the advantage that
38 resistance is less likely to occur. In addition, many viruses use similar entry routes
39 and so it is conceivable that broad-spectrum antivirals could be developed.

40 IAV belongs to the family *Orthomyxoviridae* and possesses a segmented, negative-
41 sense RNA genome. Unlike most RNA viruses, IAV replicates in the nucleus.
42 Therefore, the virus has to overcome several barriers on its way to the site of
43 replication and, simultaneously, avoid being recognized by the innate immune
44 system. IAV entry is a dynamic process which requires the completion of six
45 individual steps: Attachment to target cells (I), internalization into cellular
46 compartments (II), endosomal trafficking to the perinuclear region (III), fusion of viral

47 and endosomal membranes (IV), uncoating (V), and import of the viral genome into
48 the nucleus (VI) (fig. 1). Here, we summarize how the virus manages to successfully
49 enter target cells and to transport its genetic material to the nucleus. Furthermore, we
50 discuss which host factors are required by the virus to complete these processes and
51 which inhibitors are available to block individual steps of the IAV entry pathway.

52

53 **INFLUENZA A VIRUS ATTACHMENT TO HOST CELLS**

54 **Sialic acid is the receptor for influenza A virus**

55 The initial step of the viral entry process is the attachment of IAV to the host cell. The
56 primary receptor for IAV is N-acetylneuraminic acid (also called sialic acid) and this
57 receptor is recognized and bound by the viral membrane protein, HA (Palese and
58 Shaw 2007). Sialic acid is the distal residue in oligosaccharide chains of N- and O-
59 linked glycoproteins and –lipids. Often, sialic acid is attached to the underlying
60 galactose by α -2,3 or α -2,6 linkages. This linkage and the resulting structural
61 consequences influence how well IAV can bind to its receptor.

62 HA is a multifunctional IAV protein mediating virus attachment and fusion. There are
63 18 different HA subtypes known of which 16 circulate in waterfowl and two subtypes
64 (H17, H18) have been isolated from bats (Tong et al. 2012; Tong et al. 2013). Of
65 note H17 and H18 do not bind to sialic acid; the receptor for these viruses is not yet
66 known (Sun et al. 2013; Tong et al. 2013; Zhu et al. 2013b). HA is expressed as a
67 trimer on the virion surface. The stalk region of HA containing the fusion peptide
68 connects the HA to the virion envelope by a short hydrophobic sequence (Skehel and
69 Wiley 2000). This region is heavily glycosylated on conserved epitopes, which
70 appear to be required for stability and structure of the molecule (Roberts et al. 1993).

71 The globular head is also glycosylated but the glycosylation pattern and -type can be
72 highly variable in different HA subtypes. The receptor binding pocket (RBP) is
73 located on the distal end of the HA trimer at the globular head (fig. 2a) and is highly
74 conserved among different HA subtypes. Mutations in residues of the RBP and those
75 in close proximity can drastically alter the receptor specificity of HA (Connor et al.
76 1994; Liu et al. 2009; Xu et al. 2010). Sialic acid has been shown to occupy the
77 whole RBP and to be the major point of contact between the virus and the cell (Weis
78 et al. 1988). The interaction between sialic acid and HA is believed to be of low
79 affinity. To increase the overall strength of the interaction multiple HA molecules are
80 used to bind to several glycoproteins resulting in high avidity-binding to the cell
81 surface (Sauter et al. 1989).

82 The structure and conformation of HA determines receptor specificity of IAV. It is well
83 established that avian strains prefer sialic acid receptors with a α -2,3 linkage, while
84 human IAV strains generally possess a high receptor specificity for α -2,6 linked sialic
85 acid (Weis et al. 1988; Gamblin et al. 2004; Stevens et al. 2006b). In addition, studies
86 using glycan arrays have shown that modifications on the underlying sugar chains
87 are also recognized by HA and influence the binding of HA to sialic acid (Stevens et
88 al. 2006a). More recent data suggest that the linkage of sialic acid is not the only
89 determinant of receptor binding specificity but that the topological structure of sialic
90 acid contributes to specificity and affinity of HA binding to sialic acid. It was shown
91 that human IAV strains preferentially bind to long, umbrella-shaped sialic acid
92 molecules with α -2,6 linkage, while avian strains generally bind to short sialic acid
93 molecules that adopt a cone-like structure (Chandrasekaran et al. 2008). There are
94 also reports that alternative glycosylations can be recognized by certain IAV strains,
95 e.g. it was shown that N-glycolylneuraminic acid linked to galactose by α -2,3 linkage

96 can serve as receptor for IAV in the duck intestine (Ito et al. 2000).Recent structural
97 studies on receptor binding of H5 and H7 viruses further developed our
98 understanding of differential receptor specificity: For an H5N1 virus that had been
99 selected to transmit in the ferret model it was shown that binding of α -2,6 sialic acid
100 occurred in a similar orientation as in pandemic human viruses (Xiong et al. 2013a).
101 In contrast, the orientation of sialic acid was different when the avian H5 was
102 analyzed in combination with α -2,6 sialic acid. HA from an H7N9 virus that has
103 recently emerged in China was able to bind α -2,6 sialic acid efficiently but in a
104 different orientation compared to human pandemic viruses (Steinhauer 2013; Xiong
105 et al. 2013b). Moreover, these recent studies also suggest that not only efficient
106 binding to α -2,6 sialic acid might be required for human receptor specificity but also a
107 reduction in binding efficiency to α -2,3 sialic acid. For the impact of receptor
108 specificity on tropism, host range and pathogenicity of IAV we refer to (Matrosovich
109 et al. 2009; Imai and Kawaoka 2012; Wilks et al. 2012).

110 Often, virus entry is a multi-step process in which abundant, low affinity receptors are
111 utilized for initial contact of viral particles with the cell. Subsequently, binding of high
112 affinity receptors results in complete attachment and may trigger uptake of a particle.
113 While it is generally accepted that sialic acid is the main receptor for IAV, there is still
114 debate whether IAV requires additional host factors for successful attachment and
115 entry into target cells. It has been observed that IAV binding to sialylated receptors
116 does not always result in internalization of the virus into the host cell (Carroll and
117 Paulson 1985). Furthermore, some desialylated cells retain the ability to bind IAV
118 (Stray et al. 2000; Thompson et al. 2006) indicating that sialic acid might not be the
119 sole receptor required for IAV attachment. Annexin V and 6-sulfo sialyl Lewis X
120 receptors have been proposed as potential additional receptors for IAV attachment

121 (table 1) (Huang et al. 1996; Gambaryan et al. 2008). Furthermore, IAV was able to
122 attach to but not infect cells with a defect in complex N-glycosylation, suggesting the
123 requirement of an additional factor other than sialic acid for efficient virus infection
124 (Chu and Whittaker 2004). These results were later refined as it was found that
125 proteins containing N-linked glycans are of importance for virus entry via
126 macropinocytosis while clathrin-mediated endocytosis (both discussed later) was not
127 affected by the absence of N-linked glycosylation and that entry of IAV was
128 completely dependent on the presence of sialic acid (de Vries et al. 2012). For
129 dendritic cells and macrophages, there are studies indicating that C-type lectin
130 receptors such as macrophage mannose receptor (MMR), macrophage galactose-
131 type lectin (MGL) and **Dendritic Cell-Specific Intercellular adhesion molecule-3-
132 Grabbing Non-integrin (DC SIGN)** may also act as receptors for IAV entry (Reading
133 et al. 2000; Wang et al. 2008; Upham et al. 2010; Londrigan et al. 2011). However, it
134 remains to be determined whether these receptors alone are sufficient or whether
135 additional co-receptors are required for viral uptake.

136 **Inhibitors of virus attachment**

137 Inhibition of virus attachment might be an attractive strategy for inhibiting IAV
138 infection at the earliest step. Several approaches to block the interaction between HA
139 and sialic acid have been proposed (table 2). Inhibitors can work by either binding to
140 the HA globular head to prevent interactions with the receptor or they can act on the
141 receptor sialic acid. Monoclonal antibodies (mAbs) that bind HA are the most
142 prominent example of inhibitors acting on the virus. Numerous mAbs have been
143 generated and found to inhibit virus replication in cell culture and animal models
144 (reviewed in (Martinez et al. 2009)). Importantly, most mAbs which target the globular
145 head of HA bind and neutralize only the HA they were generated against and a few

146 closely related HAs. However, in recent years broadly neutralizing mAbs that bind
147 conserved epitopes in HA have been developed and these antibodies show promise
148 as inhibitors of many different influenza virus strains (Corti and Lanzavecchia 2013).
149 Two types of antibodies can be distinguished: Antibodies binding conserved epitopes
150 in the globular head (Yoshida et al. 2009; Whittle et al. 2011; Ekiert et al. 2012) and
151 antibodies recognizing conserved sites in the stem of HA (reviewed in (Ekiert and
152 Wilson 2012)). The latter type of antibodies do not inhibit attachment but block fusion
153 and are therefore discussed in the section on viral fusion. Antibodies that recognize
154 conserved epitopes in the globular head can block attachment of different influenza
155 virus subtypes and hold promise for the development of antiviral drugs.

156 Besides the mAbs soluble sialic acid analogues that block the RBP of HA have been
157 suggested as potent inhibitors of IAV infection. Both, soluble α -2,3 and α -2,6 linked
158 sialic acid, can be found in mucus as well as in exosomes released from airway
159 epithelial cells (Baum and Paulson 1990; Kesimer et al. 2009; Roberts et al. 2011).
160 Recent studies propose several synthetic receptor mimics that bind to the RBP for
161 use as antiviral compounds (Kimura et al. 2000; Terabayashi et al. 2006; Nicol et al.
162 2012). It was also shown that sialic acid peptide mimics that bind the RBP of HA can
163 block infection with seasonal H1N1 and H3N2 viruses (Matsubara et al. 2010).
164 Moreover, potent antiviral effects of liposomes loaded with such sialic acid analogues
165 were observed (Hendricks et al. 2013). In addition, the development of receptor-
166 binding compounds that decrease the amount of available binding partners for HA,
167 has also been followed (Matsubara et al. 2009). An interesting strategy to inhibit virus
168 attachment is the use of sialidases, which remove sialic acid from epithelial cell
169 surfaces. DAS181 is a compound consisting of a bacterial sialidase derived from
170 *Actinomyces viscosus* linked to amphiregulin that is currently in phase II clinical trials.

171 The conjugation of the sialidase to amphiregulin containing an epidermal-growth-
172 factor-like domain is required for the effective targeting of epithelial cells. DAS181
173 possesses antiviral activity against a broad variety of influenza A and B viruses in cell
174 culture (Nicholls et al. 2013).

175

176 **ENTRY ROUTES USED FOR INFLUENZA A VIRUS INTERNALIZATION**

177 **Internalization of IAV**

178 Upon attachment to the host cell IAV is taken up into the cell. Imaging studies
179 revealed early that the virus enters the cell by receptor-mediated endocytosis
180 (Patterson et al. 1979; Matlin et al. 1981; Yoshimura et al. 1982). It was shown that
181 cold-bound virus was –upon raising the temperature to 37°C- not fusing at the
182 plasma membrane. Virus uptake occurred within minutes after the temperature raise
183 as the half life time of attached viral particles to become resistant to treatment with
184 sialidases was between 10-15 minutes (Matlin et al. 1981). IAV was internalized into
185 mainly clathrin-coated but also into uncoated vesicles. This already suggested that
186 IAV is able to utilize multiple endocytosis routes, not only clathrin-mediated
187 endocytosis. Later, it was demonstrated that the virus can still infect cells defective in
188 clathrin- and caveolin-dependent pathways (Sieczkarski and Whittaker 2002). In line
189 with these data, imaging studies with single viral particles showed that IAV can utilize
190 clathrin- and non-clathrin entry routes in parallel (Rust et al. 2004). Recent studies
191 identified macropinocytosis as alternative pathway exploited by IAV (de Vries et al.
192 2011). Macropinocytosis refers to the uptake of large-sized cargo through the actin-
193 dependent formation of large endocytic vesicles called macropinosomes. IAV enters
194 the cell by clathrin-mediated endocytosis in the absence of serum and this pathway
195 can be efficiently blocked using the dynamin inhibitor dynasore. However, if serum is

196 present during infection, IAV is taken up into cells by dynamin-dependent and –
197 independent entry routes. A complete block of internalization was only achieved
198 when cells were treated with dynasore in combination with EIPA (de Vries et al.
199 2011). EIPA is an inhibitor of Na⁺/H⁺ exchangers, which was shown to block
200 macropinocytosis by preventing elevation of the cytosolic pH which in turn affects
201 activation of GTPases required for actin remodeling (Koivusalo et al. 2010). Further
202 studies showed that the choice of entry route is likely to be cell type dependent (De
203 Conto et al. 2011) and that filamentous IAV preferentially uses macropinocytosis for
204 internalization (Rossman et al. 2012). The latter can explain earlier observations on
205 the entry process of filamentous IAV: It had been demonstrated that acidification of
206 endosomes was required but dynamin seemed to be dispensable (Sieczkarski and
207 Whittaker 2005).

208 To date it is not clear whether binding of HA to sialylated glycans is sufficient to
209 initiate internalization of viral particles. Several studies indicate that additional
210 receptors may be required to orchestrate virus uptake (table 1). It was demonstrated
211 that the formation of clathrin-coated pits occurs at faster pace at virus-attached spots
212 than in other areas at the cell surface (Rust et al. 2004). These data indicate that IAV
213 specifically triggers its uptake via clathrin-mediated endocytosis and is therefore
214 likely to interact with additional cell surface receptors to activate downstream
215 signaling processes required for internalization. The adaptor protein Epsin-1
216 localizes to attachment sites of IAV and this coincides with the formation of clathrin-
217 coated pits at that site. In addition, knockdown of Epsin-1 inhibited clathrin-mediated
218 endocytosis of IAV but not of other ligands such as transferrin (Chen and Zhuang
219 2008). Therefore, Epsin-1 is an adaptor recruited specifically for clathrin-mediated

220 IAV entry indicating that IAV triggers certain pathways that differ from classical
221 clathrin-mediated endocytosis events.

222 There is growing evidence that receptor tyrosine kinases (RTKs) may play an
223 important role in the uptake of IAV particles. It could be shown that IAV attachment
224 activates EGFR and that activated EGFR promotes virus uptake into target cells.
225 Similar results were obtained for the c-Met kinase so the authors speculate that IAV
226 attachment to the cell surface results in lipid raft formation which serves as signaling
227 platform to trigger RTK activation leading to virus internalization (Eierhoff et al. 2010).
228 Recently, it has been demonstrated that activation of phosphoinositide-specific
229 phospholipase γ 1 (PLC γ 1) - which acts downstream of EGFR - is required for entry
230 of H1N1 viruses (Zhu et al. 2013a). Interestingly, in this study both, H1N1 and H3N2
231 viruses were able to activate EGFR following attachment but only H1N1 viruses also
232 activated PLC γ 1. These results indicate that different IAV subtypes are capable of
233 specifically activating distinct signaling pathways to facilitate entry. Supporting
234 evidence for involvement of RTKs in IAV entry came from inhibitor studies showing
235 that many RTK inhibitors decrease IAV internalization by macropinocytosis (de Vries
236 et al. 2011). Indeed, N-linked glycans, present on membrane receptors, have shown
237 to be important for IAV entry in the presence of serum (de Vries et al. 2012).
238 Nevertheless, the authors clearly demonstrate that IAV entry was dependent on sialic
239 acid under all experimental conditions. In summary there is evidence for activation of
240 common RTK cascades involving PKC, MEK/ERK and PI3K/AKT by IAV infection,
241 but it remains to be determined how these pathways contribute to virus entry into
242 host cells.

243

244

245 **Inhibitors of internalization**

246 Compounds that inhibit virus endocytosis would be of great clinical use as a large
247 array of viruses enter cells by endocytosis. However, most inhibitors used in tissue
248 culture experiments such as dynasore or EIPA are cytotoxic in higher concentrations
249 and prolonged exposure and are therefore not suitable for clinical use. Also RTK
250 inhibitors are problematic as most currently available compounds lack specificity and
251 target a variety of RTK. An interesting compound is Lj001 which affects membrane
252 fluidity and -curvature through (1)02-mediated lipid oxidation. Therefore, its antiviral
253 activity is restricted to enveloped viruses (Wolf et al. 2010; Vigant et al. 2013).

254

255 **ENDOSOMAL TRAFFICKING OF INFLUENZA A VIRUS**

256 **From early to late endosomes**

257 The endosomal system is well described as a cellular sorting system for incoming
258 extracellular material and intracellular vesicles (reviewed in (Mellman 1996)).
259 Influenza viruses are taken up by endocytosis or macropinocytosis and exploit the
260 transport system via distinct endosomal stages and concomitant changes in pH to
261 release their viral RNPs into the cytoplasm. Upon internalization by either uptake
262 pathway, receptor-mediated endocytosis or macropinocytosis, the virus first localizes
263 to early endosomes and then reaches late endosomes. Endosomal trafficking is
264 known to be a non-linear pathway with a multitude of different branches leading to
265 degradation of extracellular compounds and membrane recycling (Steinman et al.
266 1983). Here, we focus on how IAV exploits the endosomal pathway.

267 Before influenza A virus reaches its fusion site it has to pass different stages of the
268 endocytic machinery, which is assembled and constantly renewed around the
269 internalized virus particles (Rust et al. 2004; Cocucci et al. 2012). A difficulty in

270 detecting these stages of viral trafficking is the short time span viruses remain in the
271 endosomal compartment. Penetration of viral ribonucleoprotein complexes (vRNPs)
272 into the cytoplasm can be detected already after several minutes following virus
273 binding to the cell and vRNPs reach the nucleus within the first hour (Martin and
274 Helenius 1991). For the aim of visualizing viruses along the endosomal trafficking
275 pathway, synchronized infection was established as an important tool that allows
276 monitoring early infection events (Matlin et al. 1981). It has been demonstrated that
277 endosomal trafficking of the virus involves actin- and microtubule-dependent
278 processes (Nielsen et al. 1999; Sun and Whittaker 2007; De Conto et al. 2012).
279 Using single virus trajectories from imaging fluorescently-labelled virions, viral
280 transport was dissected into three different stages (Lakadamyali et al. 2003): First,
281 the virus is transported in the cell-periphery and this process was demonstrated to be
282 actin-dependent. This is followed by the second stage which is marked by rapid
283 dynein-directed movement. Finally, moving of virions along microtubules to the
284 perinuclear region can be defined as stage three. This transport pattern correlates to
285 a large extend with well-established endosomal routes: Early endosomes (EE)
286 containing cargo are transported away from the cell surface via actin dependent
287 transport. EEs are then transported via the motorproteins kinesin-1 and dynein along
288 microtubules towards the nucleus. Simultaneously, EEs constantly exchange
289 vesicles with the trans Golgi network thereby undergoing a maturation process
290 (reviewed in (Huotari and Helenius 2011)). Rab5 and additional proteins such as
291 EEA1 (early endosomal autoantigen 1) and PI(3)K (phosphatidyl-inositol-3-OH
292 kinase), are major regulators of this maturation process and are used as marker
293 proteins to stain EEs (fig. 3) (Bucci et al. 1992; Mu et al. 1995; Simonsen et al. 1998;
294 Christoforidis et al. 1999a; Christoforidis et al. 1999b; Fujioka et al. 2011). Late
295 endosomes (LE) are formed from EEs during their microtubule-dependent transport

296 into the perinuclear region by acquiring intraluminal vesicles during vesicle exchange
297 with lysosomes or other late endosomes (Luzio et al. 2007; Huotari and Helenius
298 2011). LE contain integral membrane proteins such as LAMP1 (lysosomal membrane
299 protein 1) and their pH drops down from 6.8-5.9 in EEs to 6.0-4.8 in LE (Maxfield and
300 Yamashiro 1987). The progression from EE to LE is indicated by the so called “Rab
301 Switch” from Rab5 for EE to Rab 7 for LE (Rink et al. 2005). Rab proteins are cellular
302 GTPases that are recruited to vesicle membranes and play a key role in regulating
303 endosomal trafficking. Different Rab proteins are required for different steps in
304 vesicular transport, although some of them are following their endosomal
305 compartments throughout maturation of endosomes (Zerial and McBride 2001).

306 With respect to IAV infection, both Rab5 and Rab7 have been shown to be required
307 (Sieczkarski and Whittaker 2003). Moreover, protein kinase C β II (PKC β II) has been
308 linked to IAV trafficking in endosomes. Infection of cells pretreated with inhibitors
309 against PKC β II leads to the accumulation of viral particles in LE, without fusion taking
310 place (Sieczkarski et al. 2003). Other important players in LE trafficking are histone
311 deacetylases. Depletion of histone deacetylase 8 (HDAC8) resulted in dysregulation
312 of microtubule organization, centrosome function and maturation of LE to lysosomes
313 and subsequently in a decrease in viral replication (Yamauchi et al. 2011).
314 Furthermore, Cullin 3 which is a scaffolding protein for an E3 ubiquitin ligase complex
315 was shown to be required for IAV entry at the level of LE (Huotari et al. 2012).
316 Importantly, depletion of cullin 3 also inhibited trafficking of other cargos such as
317 epidermal growth factor (EGF) indicating that this pathway is required for transport of
318 a variety of cargos and is not solely used by IAV.

319 **FUSION OF INFLUENZA A VIRUS**

320 **Fusion between viral and endosomal membrane**

321 Preceding the nuclear transport of IAV fusion of viral and endosomal membranes is
322 required to release vRNPs into the cytoplasm. This process is driven by a low pH
323 environment and the class I fusion protein of IAV, the HA. LE posses an acidic
324 environment and thus facilitate the induction of influenza virus HA-dependent fusion
325 at pH 5.0 (Maeda and Ohnishi 1980; Daniels et al. 1985; White and Wilson 1987).
326 Interestingly, HAs of different subtypes display varying pH optima for fusion and HAs
327 of human isolates require lower pHs than avian isolates of the same subtype
328 (Galloway et al. 2013). During the acidification process of endosomes, proton pumps
329 which deliver protons into the endosomal lumen and thereby ensure stepwise
330 acidification, exhibit a crucial function (Galloway et al. 1983; Perez and Carrasco
331 1994). These so called v-ATPases consist of two complexes, one membrane
332 associated V0 complex and a soluble cytosolic V1 complex, which hydrolyzes ATP
333 as the driving force of acidification (reviewed in (Forgac 2007)). Once IAV is in the
334 acidic environment of LE, HA undergoes conformational changes which expose the
335 fusion peptide and position it towards the endosomal membrane (fig. 2b) (Carr and
336 Kim 1993; Bullough et al. 1994; Chen et al. 1999). It was shown that intermediate
337 stages dependent on pH and membrane proximity exist (Korte et al. 1999; Leikina et
338 al. 2002). Following the final conformational changes, the fusion peptide is inserted
339 into the target membrane which brings the viral and endosomal membranes into
340 close proximity (Tsurudome et al. 1992; Weber et al. 1994; Durrer et al. 1996). Of
341 note, while the crystal structures of pre- and post-fusion HA have been solved the
342 structures of the intermediate stages are not known so far and can only be modeled
343 based on the pre- and post-fusion structures. For the fusion process it was shown

344 that several HA trimers promote membrane fusion by simultaneous conformational
345 changes and release of folding energy (Markovic et al. 2001). To proceed with fusion
346 between viral and endosomal membranes, HA trimers tilt at the fusion site and the
347 outer leaflets of the membranes interact with each other in a hemifusion stage
348 (Tatulian et al. 1995; Chernomordik et al. 1998). Finally, both membranes fuse and a
349 so-called fusion pore is established (Spruce et al. 1989; Melikyan et al. 1993a;
350 Melikyan et al. 1993b). Through this fusion pore vRNPs can be released into the
351 cytoplasm.

352 Limited information is available regarding cellular factors required for fusion of IAV.
353 As discussed above, the vATPase complex is essential for acidification of the
354 endosome, a prerequisite for fusion. Only very recently, the tetraspanin CD81 has
355 been identified as another cellular player in the fusion process (He et al. 2013).
356 Approximately 50% of internalized IAV localized to CD81- and Rab5-positive
357 endosomes and fusion was observed to occur in these vesicles. In the absence of
358 CD81 fusion was reduced by 50%. It is currently unknown how CD81 contributes to
359 fusion but CD81 seems to mark a productive entry route for IAV.

360 **Inhibitors of fusion**

361 Inhibition of viral fusion can be achieved by inhibition of acidification in endosomes
362 (table 2). One of the most potent inhibitors for this purpose is Bafilomycin A1 (BafA1).
363 Bafilomycins belong to the family of macrolide antibiotics that were shown to inhibit
364 vacuolar-type proton pumps involved in viral entry (Bowman et al. 1988; Ochiai et al.
365 1995). Similar effects were shown for diphyllin and SaliPhe, other v-type ATPase
366 inhibitors (Huss and Wieczorek 2009; Konig et al. 2010; Muller et al. 2011). Small
367 molecules that bind to the stem region of HA and thereby hinder the conformational
368 changes required for fusion represent another class of fusion inhibitors. The first

369 compound of this group to be discovered was TBHQ which has been crystallized in
370 complex with HA (Bodian et al. 1993; Russell et al. 2008). Later on, several
371 compounds that act in a similar way have been described: BMY-27709, CL-385319,
372 RO5464466, stachyflin and 4c (Luo et al. 1997; Plotch et al. 1999; Yoshimoto et al.
373 1999; Vanderlinden et al. 2010; Zhu et al. 2011). Unfortunately, resistance mutations
374 in HA can develop rapidly within few passages of the virus and confer resistance to
375 this type of compound. Arbidol has also been identified as an inhibitor of membrane
376 fusion. Mutations rendering viruses resistant to arbidol have been mapped to HA and
377 seem to impact acid stability of HA (Leneva et al. 2009). Of note, arbidol is approved
378 as anti-influenza drug in Russia. Alternatively, the stem region of HA can be targeted
379 by broadly neutralizing antibodies as mentioned above (Corti and Lanzavecchia
380 2013). Such antibodies bind to a region of HA that is conserved even between
381 different subtypes and this enables the antibodies' potential to inhibit many different
382 strains of IAV (Okuno et al. 1993; Throsby et al. 2008; Ekiert et al. 2009; Sui et al.
383 2009; Corti et al. 2011). While they do not prevent binding to the host cell they
384 interfere with the conformational changes required for fusion. These antibodies
385 represent promising drug candidates but also could help to design a vaccine that
386 provides protection against a broad range of IAV strains.

387

388 **UNCOATING**

389 **Release of vRNPs into the cytoplasm**

390 Upon fusion of viral and endosomal membranes IAV uncoating is completed with the
391 release of the viral RNPs into the cytosol. This process requires coordinated action of
392 the viral proteins M2 and M1. In the intact virus particle M1 forms a structured layer
393 underneath the viral membrane which can be visualized by electron microscopy

394 (Ruigrok et al. 2000; Calder et al. 2010; Fontana et al. 2012; Fontana and Steven
395 2013). It is assumed that M1 plays a crucial role for the architecture of the virion by
396 linking the viral membrane containing the glycoproteins with the RNPs in the virus
397 core. While the expression of viral glycoproteins can result in production of virus-like
398 particles even in the absence of M1 the matrix protein is required for production of
399 infectious virions (virus assembly is reviewed in (Rossman and Lamb 2011)). This is
400 supported by the observation that M1 determines the shape of the virion: Exchange
401 of M1 is sufficient to change the morphology of virions from spherical to filamentous
402 (Roberts et al. 1998; Bourmakina and Garcia-Sastre 2003; Elleman and Barclay
403 2004). It is currently unclear how M1 interacts with the viral membrane and/or
404 glycoproteins; specific binding domains have not yet been mapped (Zhang and Lamb
405 1996; Schmitt and Lamb 2005). For the interaction of M1 with the vRNPs it could be
406 demonstrated that the middle domain of M1 is responsible for binding to NP on the
407 RNP (Noton et al. 2007).

408 During the uncoating process the interaction of M1 with the viral membrane as well
409 as the interaction of M1 with the vRNPs has to be released in order to allow complete
410 uncoating and subsequent transport of the RNPs into the nucleus. This requires the
411 activity of the viral protein M2. M2 was identified in 1981 as the second protein
412 encoded by segment 7 of IAV (Lamb and Choppin 1981). It was found to form
413 tetramers that are present in virions (Zebedee and Lamb 1988; Holsinger and Lamb
414 1991; Sugrue and Hay 1991) and it was described to possess ion channel activity
415 selective for monovalent ions (Pinto et al. 1992; Chizhnikov et al. 1996).
416 Interestingly, the ion channel activity of M2 is regulated by pH: With lower pH the ion
417 channel activity increases and histidine 37 of M2 is crucial for this regulation (Pinto et
418 al. 1992). The transmembrane pore of the channel is lined by a series of amino

419 acids that all lie on the same side of an alpha-helix; four of these helices from the
420 four monomers form the channel (Grambas et al. 1992; Pinto et al. 1992; Wang et al.
421 1993; Stouffer et al. 2008). During the entry process of IAV the ion channel activity of
422 M2 is required for uncoating: Upon acidification of the endosome M2 mediates proton
423 influx from the endosome into the virion resulting in a decrease of the pH within the
424 virus particle (Wharton et al. 1994). This M2-mediated change in pH is required for
425 the detachment of M1 from the vRNPs resulting in the release of the vRNPs into the
426 cytoplasm (Zhirnov 1990). Furthermore, it was observed that M1 separates from the
427 RNPs before they are imported into the nucleus (Bukrinskaya et al. 1982; Martin and
428 Helenius 1991). Interestingly, this initial RNP nuclear import can be blocked by
429 expression of M1 but brief low pH treatment can in turn relieve the block mediated by
430 M1 (Bui et al. 1996). These observations have lead to the current model in which the
431 pH drop in the virion within the endosome causes conformational changes in M1 and
432 subsequently the interaction between the RNPs and M1 is weakened or lost. The
433 changes in M1 conformation have been visualized by electron microscopy: The
434 helical structure of the M1 layer in the virion is lost in acid-treated virions (Calder et
435 al. 2010; Fontana et al. 2012). Before the loss of the M1 structure rearrangements in
436 the M1 layer could be detected (Fontana and Steven 2013). It is currently unclear
437 how the conformational change occurs but it was suggested that the linker region
438 between the N- and C-terminal domain of M1 is important: *In vitro* the linker peptide
439 changed its conformation upon pH drop but only in the presence of zinc ions, which
440 have been detected in influenza virions (Elster et al. 1994; Okada et al. 2003). Not
441 much is known about the involvement of cellular factors in this process yet. Very
442 recently, the E3 ubiquitin ligase Itch was reported to be required for efficient
443 uncoating (Su et al. 2013). The authors could demonstrate that Itch gets

444 phosphorylated and recruited to endosomes upon IAV infection where it ubiquitinates
445 M1 and thereby facilitates release of the vRNPs.

446 **Inhibitors of uncoating**

447 Amantadine is the best known example for an inhibitor of M2. Its antiviral activity was
448 first described in 1964 (Davies et al. 1964). Later it was found that it targets the M2
449 protein of influenza A virus and thereby exerts its antiviral function (Skehel et al.
450 1978; Hay et al. 1985). Rimantadine is structurally similar and also blocks M2;
451 together this drug class is called adamantanes. Unfortunately, resistance to the
452 adamantanes can be achieved by just a single amino acid change in M2 and this has
453 no or very little impact on viral fitness (Hay et al. 1986; Hayden et al. 1991; Sweet et
454 al. 1991). Moreover, resistance to the adamantanes is widespread since the
455 beginning of the 21st century and therefore current guidelines do not recommend the
456 use of adamantanes (Bright et al. 2005). A recent study reported on the development
457 of novel M2 inhibitors that can block adamantane-sensitive as well as resistant
458 strains (Wang et al. 2013). It is therefore conceivable that novel M2-inhibiting drugs
459 might become available for clinical use in the future (table 2).

460

461 **NUCLEAR IMPORT OF VIRAL RNPs**

462 **Import of vRNPs into the nucleus**

463 After completion of the uncoating process the RNPs are transported into the nucleus.
464 Already early studies observed that NP accumulates in the nucleus while M1
465 distributes between cytoplasm and nucleus (Martin and Helenius 1991). Given the
466 size of the vRNPs it was hypothesized that an active, energy-dependent process
467 would mediate their import. Of note, also RNPs microinjected into the cytoplasm of

468 cells were capable of entering the nucleus (Kemler et al. 1994). In 1995, O'Neill and
469 co-workers demonstrated that the viral RNA was not able to enter the nucleus;
470 addition of NP was required. Moreover, they could show that at 0°C NP docks to the
471 nuclear envelope in the presence of karyopherins and is imported into the nucleus
472 upon addition of the cellular import factors Ran and p10 proteins and a temperature
473 shift to 20°C (O'Neill et al. 1995). This clearly showed that viral RNPs are imported
474 via the cellular karyopherin import pathway. All protein components of the RNP, the
475 three polymerase subunits and NP, possess nuclear localization signals (NLS).
476 Nevertheless, import of the RNP only depends on the NLS in NP (O'Neill et al. 1995;
477 Cros and Palese 2003). First, an unconventional NLS in the N-terminus was
478 described in NP (Wang et al. 1997). Later on, a second bi-partite NLS was identified
479 between amino acids 198-216 (Weber et al. 1998) as well as a third one around
480 amino acids 320-400 (Bullido et al. 2000). For import of the RNPs the unconventional
481 NLS seems to be the most important one (Cros and Palese 2003). On the cellular
482 side karyopherins alpha 1, alpha 3 and alpha 5 have been identified as the main
483 importins for RNPs (table 1) (O'Neill et al. 1995; Wang et al. 1997; Melen et al. 2003).
484 Also CSE1L, a cellular factor required for cycling of karyopherins between nucleus
485 and cytoplasm, has been shown to be required for import of RNPs early in infection
486 (Konig et al. 2010). Later in infection when the individual polymerase proteins get
487 imported the NLS on the polymerase subunits become important and other
488 karyopherins are involved. This topic is reviewed in (Hutchinson and Fodor 2012).
489 Upon import into the nucleus the karyopherins bind to RanGTP, which results in
490 release of cargo and this marks the end of the viral entry process.

491

492 **OUTLOOK**

493 Entry of IAV into target cells is the very first step of the viral life cycle and as such is
494 crucial for the establishment of infection. The receptor specificity of the virus' HA
495 determines tropism of the virus, thereby contributing to outcome of disease, and
496 potentially virus spread between susceptible hosts. In recent years our understanding
497 of the differential receptor specificity between avian and mammalian influenza
498 viruses has greatly improved and exciting structural insights have been obtained.
499 However, more work is still required to fully understand and predict receptor
500 specificity of all HA subtypes. For entry into target cells the virus relies on and
501 exploits existing cellular pathways of transporting cargo, thus the entry process is a
502 complex interplay between virus and host cell. Advances in live cell microscopy are
503 of great value in tracking virions during entry in real-time and in monitoring the
504 interaction of the virus with cellular factors and compartments. Novel findings indicate
505 that virus uptake and -trafficking may not be equal to that of other cargo transported
506 into the cell. Instead, IAV specifically recruits factors facilitating entry and activates
507 signaling molecules such as RTKs within minutes after infection. Future studies will
508 shed light on how these host factors contribute to virus entry on a molecular level.
509 The increasing insight into these processes can be exploited to develop means of
510 inhibiting the virus early in infection. Novel treatment options may be specifically
511 directed against IAV, or be of broad antiviral efficacy if targeting entry routes used by
512 several viruses. In the near future, we may obtain a detailed insight into the cell
513 biology of IAV entry and profit from newly developed antivirals targeting host factors
514 rather than viral proteins, thereby minimizing the occurrence of resistance as
515 observed with the M2 and NA inhibitors.

516

517 **ACKNOWLEDGEMENTS**

518 We would like to thank Dr. U. Ziegler from the Center for Microscopy and Image
519 Analysis at the University of Zurich for help with super resolution microscopy, Dr.
520 Lars Hangartner, University of Zurich, for help with structural modelling and Dr. Ben
521 Hale, MRC – University of Glasgow Centre for Virus Research, and Dr. Jovan
522 Pavlovic, University of Zurich, for critical reading of the manuscript.

REFERENCES

- 523 **Baum, L. G. and J. C. Paulson (1990).** "Sialyloligosaccharides of the respiratory epithelium in the
524 selection of human influenza virus receptor specificity." *Acta Histochem Suppl* **40**: 35-38.
- 525 **Bodian, D. L., R. B. Yamasaki, R. L. Buswell, J. F. Stearns, J. M. White and I. D. Kuntz (1993).**
526 "Inhibition of the fusion-inducing conformational change of influenza hemagglutinin by
527 benzoquinones and hydroquinones." *Biochemistry* **32**(12): 2967-2978.
- 528 **Bourmakina, S. V. and A. Garcia-Sastre (2003).** "Reverse genetics studies on the filamentous
529 morphology of influenza A virus." *J Gen Virol* **84**(Pt 3): 517-527.
- 530 **Bowman, E. J., A. Siebers and K. Altendorf (1988).** "Bafilomycins: a class of inhibitors of membrane
531 ATPases from microorganisms, animal cells, and plant cells." *Proc Natl Acad Sci U S A* **85**(21):
532 7972-7976.
- 533 **Bright, R. A., M. J. Medina, X. Xu, G. Perez-Orozco, T. R. Wallis, X. M. Davis, L. Povinelli, N. J. Cox
534 and A. I. Klimov (2005).** "Incidence of adamantane resistance among influenza A (H3N2)
535 viruses isolated worldwide from 1994 to 2005: a cause for concern." *Lancet* **366**(9492): 1175-
536 1181.
- 537 **Bucci, C., R. G. Parton, I. H. Mather, H. Stunnenberg, K. Simons, B. Hoflack and M. Zerial (1992).**
538 "The small GTPase rab5 functions as a regulatory factor in the early endocytic pathway." *Cell*
539 **70**(5): 715-728.
- 540 **Bui, M., G. Whittaker and A. Helenius (1996).** "Effect of M1 protein and low pH on nuclear transport
541 of influenza virus ribonucleoproteins." *J. Virol.* **70**: 8391-8401.
- 542 **Bukrinskaya, A. G., N. K. Vorkunova, G. V. Kornilayeva, R. A. Narmanbetova and G. K. Vorkunova
543 (1982).** "Influenza virus uncoating in infected cells and effect of rimantadine." *J Gen Virol*
544 **60**(Pt 1): 49-59.
- 545 **Bullido, R., P. Gomez-Puertas, C. Albo and A. Portela (2000).** "Several protein regions contribute to
546 determine the nuclear and cytoplasmic localization of the influenza A virus nucleoprotein." *J*
547 *Gen Virol* **81**(Pt 1): 135-142.
- 548 **Bullough, P. A., F. M. Hughson, J. J. Skehel and D. C. Wiley (1994).** "Structure of influenza
549 hemagglutinin at the pH of membrane fusion." *Nature* **371**: 37-43.
- 550 **Calder, L. J., S. Wasilewski, J. A. Berriman and P. B. Rosenthal (2010).** "Structural organization of a
551 filamentous influenza A virus." *Proc Natl Acad Sci U S A* **107**(23): 10685-10690.
- 552 **Carr, C. M. and P. S. Kim (1993).** "A Spring-Loaded Mechanism for the Conformational Change of
553 Influenza Hemagglutinin." *Cell* **73**: 823-832.
- 554 **Carroll, S. M. and J. C. Paulson (1985).** "Differential infection of receptor-modified host cells by
555 receptor-specific influenza viruses." *Virus Res* **3**(2): 165-179.
- 556 **Chandrasekaran, A., A. Srinivasan, R. Raman, K. Viswanathan, S. Raguram, T. M. Tumpey, V.
557 Sasisekharan and R. Sasisekharan (2008).** "Glycan topology determines human adaptation of
558 avian H5N1 virus hemagglutinin." *Nat Biotechnol* **26**(1): 107-113.
- 559 **Chen, C. and X. Zhuang (2008).** "Epsin 1 is a cargo-specific adaptor for the clathrin-mediated
560 endocytosis of the influenza virus." *Proc Natl Acad Sci U S A* **105**(33): 11790-11795.
- 561 **Chen, J., J. J. Skehel and D. C. Wiley (1999).** "N- and C-terminal residues combine in the fusion-pH
562 influenza hemagglutinin HA(2) subunit to form an N cap that terminates the triple-stranded
563 coiled coil." *Proc Natl Acad Sci U S A* **96**(16): 8967-8972.
- 564 **Chernomordik, L. V., V. A. Frolov, E. Leikina, P. Bronk and J. Zimmerberg (1998).** "The pathway of
565 membrane fusion catalyzed by influenza hemagglutinin: restriction of lipids, hemifusion, and
566 lipidic fusion pore formation." *J Cell Biol* **140**(6): 1369-1382.
- 567 **Chizhmakov, I. V., F. M. Geraghty, D. C. Ogden, A. Hayhurst, M. Antoniou and A. J. Hay (1996).**
568 "Selective proton permeability and pH regulation of the influenza virus M2 channel
569 expressed in mouse erythroleukaemia cells." *J Physiol* **494** (Pt 2): 329-336.
- 570 **Chou, Y. Y., N. S. Heaton, Q. Gao, P. Palese, R. Singer and T. Lionnet (2013).** "Colocalization of
571 different influenza viral RNA segments in the cytoplasm before viral budding as shown by
572 single-molecule sensitivity FISH analysis." *PLoS Pathog* **9**(5): e1003358.

573 **Christoforidis, S., H. M. McBride, R. D. Burgoyne and M. Zerial (1999a).** "The Rab5 effector EEA1 is a
574 core component of endosome docking." *Nature* **397**(6720): 621-625.

575 **Christoforidis, S., M. Miaczynska, K. Ashman, M. Wilm, L. Zhao, S. C. Yip, M. D. Waterfield, J. M.**
576 **Backer and M. Zerial (1999b).** "Phosphatidylinositol-3-OH kinases are Rab5 effectors." *Nat*
577 *Cell Biol* **1**(4): 249-252.

578 **Chu, V. C. and G. R. Whittaker (2004).** "Influenza virus entry and infection require host cell N-linked
579 glycoprotein." *Proc Natl Acad Sci U S A* **101**(52): 18153-18158.

580 **Clementi, N., E. Criscuolo, M. Castelli, N. Mancini, M. Clementi and R. Burioni (2012).** "Influenza B-
581 cells protective epitope characterization: a passkey for the rational design of new broad-
582 range anti-influenza vaccines." *Viruses* **4**(11): 3090-3108.

583 **Cocucci, E., F. Aguet, S. Boulant and T. Kirchhausen (2012).** "The first five seconds in the life of a
584 clathrin-coated pit." *Cell* **150**(3): 495-507.

585 **Connor, R. J., Y. Kawaoka, R. G. Webster and J. C. Paulson (1994).** "Receptor specificity in human,
586 avian, and equine H2 and H3 influenza virus isolates." *Virology* **205**(1): 17-23.

587 **Corti, D. and A. Lanzavecchia (2013).** "Broadly neutralizing antiviral antibodies." *Annu Rev Immunol*
588 **31**: 705-742.

589 **Corti, D., J. Voss, S. J. Gamblin, G. Codoni, A. Macagno, D. Jarrossay, S. G. Vachieri, D. Pinna, A.**
590 **Minola, et al. (2011).** "A neutralizing antibody selected from plasma cells that binds to group
591 1 and group 2 influenza A hemagglutinins." *Science* **333**(6044): 850-856.

592 **Cros, J. F. and P. Palese (2003).** "Trafficking of viral genomic RNA into and out of the nucleus:
593 influenza, Thogoto and Borna disease viruses." *Virus Res* **95**(1-2): 3-12.

594 **Daniels, R. S., J. C. Downie, A. J. Hay, M. Knossow, J. J. Skehel, M. L. Wang and D. C. Wiley (1985).**
595 "Fusion mutants of the influenza virus hemagglutinin glycoprotein." *Cell* **40**(2): 431-439.

596 **Davies, W. L., R. R. Grunert, R. F. Haff, J. W. McGahen, E. M. Neumayer, M. Paulshock, J. C. Watts,**
597 **T. R. Wood, E. C. Hermann, et al. (1964).** "Antiviral Activity of 1-Adamantanamine
598 (Amantadine)." *Science* **144**(3620): 862-863.

599 **De Conto, F., S. Covan, M. C. Arcangeletti, G. Orlandini, R. Gatti, G. Dettori and C. Chezzi (2011).**
600 "Differential infectious entry of human influenza A/NWS/33 virus (H1N1) in mammalian
601 kidney cells." *Virus Res* **155**(1): 221-230.

602 **De Conto, F., E. Di Lonardo, M. C. Arcangeletti, C. Chezzi, M. C. Medici and A. Calderaro (2012).**
603 "Highly dynamic microtubules improve the effectiveness of early stages of human influenza
604 A/NWS/33 virus infection in LLC-MK2 cells." *PLoS One* **7**(7): e41207.

605 **de Vries, E., R. P. de Vries, M. J. Wienholts, C. E. Floris, M. S. Jacobs, A. van den Heuvel, P. J. Rottier**
606 **and C. A. de Haan (2012).** "Influenza A virus entry into cells lacking sialylated N-glycans."
607 *Proc Natl Acad Sci U S A* **109**(19): 7457-7462.

608 **de Vries, E., D. M. Tscherne, M. J. Wienholts, V. Cobos-Jimenez, F. Scholte, A. Garcia-Sastre, P. J.**
609 **Rottier and C. A. de Haan (2011).** "Dissection of the influenza A virus endocytic routes
610 reveals macropinocytosis as an alternative entry pathway." *PLoS Pathog* **7**(3): e1001329.

611 **Durrer, P., C. Galli, S. Hoenke, C. Corti, R. Gluck, T. Vorherr and J. Brunner (1996).** "H⁺-induced
612 membrane insertion of influenza virus hemagglutinin involves the HA2 amino-terminal fusion
613 peptide but not the coiled coil region." *J Biol Chem* **271**(23): 13417-13421.

614 **Eierhoff, T., E. R. Hrinčius, U. Rescher, S. Ludwig and C. Ehrhardt (2010).** "The epidermal growth
615 factor receptor (EGFR) promotes uptake of influenza A viruses (IAV) into host cells." *PLoS*
616 *Pathog* **6**(9): e1001099.

617 **Ekiert, D. C., G. Bhabha, M. A. Elsliger, R. H. Friesen, M. Jongeneelen, M. Throsby, J. Goudsmit and**
618 **I. A. Wilson (2009).** "Antibody recognition of a highly conserved influenza virus epitope."
619 *Science* **324**(5924): 246-251.

620 **Ekiert, D. C., A. K. Kashyap, J. Steel, A. Rubrum, G. Bhabha, R. Khayat, J. H. Lee, M. A. Dillon, R. E.**
621 **O'Neil, et al. (2012).** "Cross-neutralization of influenza A viruses mediated by a single
622 antibody loop." *Nature* **489**(7417): 526-532.

623 **Ekiert, D. C. and I. A. Wilson (2012).** "Broadly neutralizing antibodies against influenza virus and
624 prospects for universal therapies." *Curr Opin Virol* **2**(2): 134-141.

625 **Elleman, C. J. and W. S. Barclay (2004).** "The M1 matrix protein controls the filamentous phenotype
626 of influenza A virus." *Virology* **321**(1): 144-153.

627 **Elster, C., E. Fourest, F. Baudin, K. Larsen, S. Cusack and R. W. Ruigrok (1994).** "A small percentage
628 of influenza virus M1 protein contains zinc but zinc does not influence in vitro M1-RNA
629 interaction." *J Gen Virol* **75 (Pt 1)**: 37-42.

630 **Fontana, J., G. Cardone, J. B. Heymann, D. C. Winkler and A. C. Steven (2012).** "Structural changes in
631 Influenza virus at low pH characterized by cryo-electron tomography." *J Virol* **86**(6): 2919-
632 2929.

633 **Fontana, J. and A. C. Steven (2013).** "At low pH, influenza virus matrix protein M1 undergoes a
634 conformational change prior to dissociating from the membrane." *J Virol* **87**(10): 5621-5628.

635 **Forgac, M. (2007).** "Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology." *Nat*
636 *Rev Mol Cell Biol* **8**(11): 917-929.

637 **Fujioka, Y., M. Tsuda, T. Hattori, J. Sasaki, T. Sasaki, T. Miyazaki and Y. Ohba (2011).** "The Ras-PI3K
638 signaling pathway is involved in clathrin-independent endocytosis and the internalization of
639 influenza viruses." *PLoS One* **6**(1): e16324.

640 **Galloway, C. J., G. E. Dean, M. Marsh, G. Rudnick and I. Mellman (1983).** "Acidification of
641 macrophage and fibroblast endocytic vesicles in vitro." *Proc Natl Acad Sci U S A* **80**(11): 3334-
642 3338.

643 **Galloway, S. E., M. L. Reed, C. J. Russell and D. A. Steinhauer (2013).** "Influenza HA subtypes
644 demonstrate divergent phenotypes for cleavage activation and pH of fusion: implications for
645 host range and adaptation." *PLoS Pathog* **9**(2): e1003151.

646 **Gambaryan, A. S., A. B. Tuzikov, G. V. Pazygina, J. A. Desheva, N. V. Bovin, M. N. Matrosovich and**
647 **A. I. Klimov (2008).** "6-sulfo sialyl Lewis X is the common receptor determinant recognized by
648 H5, H6, H7 and H9 influenza viruses of terrestrial poultry." *Virology* **5**: 85.

649 **Gamblin, S. J., L. F. Haire, R. J. Russell, D. J. Stevens, B. Xiao, Y. Ha, N. Vasisht, D. A. Steinhauer, R. S.**
650 **Daniels, et al. (2004).** "The structure and receptor binding properties of the 1918 influenza
651 hemagglutinin." *Science* **303**(5665): 1838-1842.

652 **Gottlieb, T. A., I. E. Ivanov, M. Adesnik and D. D. Sabatini (1993).** "Actin microfilaments play a
653 critical role in endocytosis at the apical but not the basolateral surface of polarized epithelial
654 cells." *J Cell Biol* **120**(3): 695-710.

655 **Grambas, S., M. S. Bennett and A. J. Hay (1992).** "Influence of Amantadine Resistance Mutations on
656 the pH Regulatory Function of the M2-Protein of Influenza-A Viruses." *Virology* **191**: 541-549.

657 **Guinea, R. and L. Carrasco (1995).** "Requirement for vacuolar proton-ATPase activity during entry of
658 influenza virus into cells." *J Virol* **69**(4): 2306-2312.

659 **Hay, A. J., A. J. Wolstenholme, J. J. Skehel and M. H. Smith (1985).** "The molecular basis of the
660 specific anti-influenza action of amantadine." *Embo J* **4**(11): 3021-3024.

661 **Hay, A. J., M. C. Zambon, A. J. Wolstenholme, J. J. Skehel and M. H. Smith (1986).** "Molecular basis
662 of resistance of influenza A viruses to amantadine." *J Antimicrob Chemother* **18 Suppl B**: 19-
663 29.

664 **Hayden, F. G., S. J. Sperber, R. B. Belshe, R. D. Clover, A. J. Hay and S. Pyke (1991).** "Recovery of
665 drug-resistant influenza A virus during therapeutic use of rimantadine." *Antimicrob Agents*
666 *Chemother* **35**(9): 1741-1747.

667 **He, J., E. Sun, M. V. Bujny, D. Kim, M. W. Davidson and X. Zhuang (2013).** "Dual function of CD81 in
668 influenza virus uncoating and budding." *PLoS Pathog* **9**(10): e1003701.

669 **Hendricks, G. L., K. L. Weirich, K. Viswanathan, J. Li, Z. H. Shriver, J. Ashour, H. L. Ploegh, E. A. Kurt-**
670 **Jones, D. K. Fygenon, et al. (2013).** "Sialylneolacto-N-tetraose c (LSTc)-bearing liposomal
671 decoys capture influenza A virus." *J Biol Chem* **288**(12): 8061-8073.

672 **Holsinger, L. J. and R. A. Lamb (1991).** "Influenza virus M2 integral membrane protein is a
673 homotetramer stabilized by formation of disulfide bonds." *Virology* **183**(1): 32-43.

674 **Huang, R. T., B. Lichtenberg and O. Rick (1996).** "Involvement of annexin V in the entry of influenza
675 viruses and role of phospholipids in infection." *FEBS Lett* **392**(1): 59-62.

676 **Huotari, J. and A. Helenius (2011).** "Endosome maturation." *Embo J* **30**(17): 3481-3500.

677 **Huotari, J., N. Meyer-Schaller, M. Hubner, S. Stauffer, N. Katheder, P. Horvath, R. Mancini, A.**
678 **Helenius and M. Peter (2012).** "Cullin-3 regulates late endosome maturation." *Proc Natl*
679 *Acad Sci U S A* **109**(3): 823-828.

680 **Huss, M. and H. Wiczorek (2009).** "Inhibitors of V-ATPases: old and new players." *J Exp Biol* **212**(Pt
681 3): 341-346.

682 **Hutchinson, E. C. and E. Fodor (2012).** "Nuclear import of the influenza A virus transcriptional
683 machinery." *Vaccine* **30**(51): 7353-7358.

684 **Imai, M. and Y. Kawaoka (2012).** "The role of receptor binding specificity in interspecies transmission
685 of influenza viruses." *Curr Opin Virol* **2**(2): 160-167.

686 **Ito, T., Y. Suzuki, T. Suzuki, A. Takada, T. Horimoto, K. Wells, H. Kida, K. Otsuki, M. Kiso, et al.**
687 **(2000).** "Recognition of N-glycolylneuraminic acid linked to galactose by the alpha2,3 linkage
688 is associated with intestinal replication of influenza A virus in ducks." *J Virol* **74**(19): 9300-
689 9305.

690 **Kemler, I., G. Whittaker and A. Helenius (1994).** "Nuclear import of microinjected influenza virus
691 ribonucleoproteins." *Virology* **202**(2): 1028-1033.

692 **Kesimer, M., M. Scull, B. Brighton, G. DeMaria, K. Burns, W. O'Neal, R. J. Pickles and J. K. Sheehan**
693 **(2009).** "Characterization of exosome-like vesicles released from human tracheobronchial
694 ciliated epithelium: a possible role in innate defense." *FASEB J* **23**(6): 1858-1868.

695 **Kimura, K., S. Mori, K. Tomita, K. Ohno, K. Takahashi, S. Shigeta and M. Terada (2000).** "Antiviral
696 activity of NMSO3 against respiratory syncytial virus infection in vitro and in vivo." *Antiviral*
697 *Res* **47**(1): 41-51.

698 **Koivusalo, M., C. Welch, H. Hayashi, C. C. Scott, M. Kim, T. Alexander, N. Touret, K. M. Hahn and S.**
699 **Grinstein (2010).** "Amiloride inhibits macropinocytosis by lowering submembranous pH and
700 preventing Rac1 and Cdc42 signaling." *J Cell Biol* **188**(4): 547-563.

701 **Konig, R., S. Stertz, Y. Zhou, A. Inoue, H. H. Hoffmann, S. Bhattacharyya, J. G. Alamares, D. M.**
702 **Tscherne, M. B. Ortigoza, et al. (2010).** "Human host factors required for influenza virus
703 replication." *Nature* **463**(7282): 813-817.

704 **Korte, T., K. Ludwig, F. P. Booy, R. Blumenthal and A. Herrmann (1999).** "Conformational
705 intermediates and fusion activity of influenza virus hemagglutinin." *J Virol* **73**(6): 4567-4574.

706 **Lakadamyali, M., M. J. Rust, H. P. Babcock and X. Zhuang (2003).** "Visualizing infection of individual
707 influenza viruses." *Proc Natl Acad Sci U S A* **100**(16): 9280-9285.

708 **Lamb, R. A. and P. W. Choppin (1981).** "Identification of a second protein (M2) encoded by RNA
709 segment 7 of influenza virus." *Virology* **112**(2): 729-737.

710 **Leikina, E., C. Ramos, I. Markovic, J. Zimmerberg and L. V. Chernomordik (2002).** "Reversible stages
711 of the low-pH-triggered conformational change in influenza virus hemagglutinin." *Embo J*
712 **21**(21): 5701-5710.

713 **Leneva, I. A., R. J. Russell, Y. S. Boriskin and A. J. Hay (2009).** "Characteristics of arbidol-resistant
714 mutants of influenza virus: implications for the mechanism of anti-influenza action of
715 arbidol." *Antiviral Res* **81**(2): 132-140.

716 **Liu, J., D. J. Stevens, L. F. Haire, P. A. Walker, P. J. Coombs, R. J. Russell, S. J. Gamblin and J. J.**
717 **Skehel (2009).** "Structures of receptor complexes formed by hemagglutinins from the Asian
718 Influenza pandemic of 1957." *Proc Natl Acad Sci U S A* **106**(40): 17175-17180.

719 **Londrigan, S. L., S. G. Turville, M. D. Tate, Y. M. Deng, A. G. Brooks and P. C. Reading (2011).** "N-
720 linked glycosylation facilitates sialic acid-independent attachment and entry of influenza A
721 viruses into cells expressing DC-SIGN or L-SIGN." *J Virol* **85**(6): 2990-3000.

722 **Luo, G., A. Torri, W. E. Harte, S. Danetz, C. Cianci, L. Tiley, S. Day, D. Mullaney, K. L. Yu, et al. (1997).**
723 "Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus."
724 *J Virol* **71**(5): 4062-4070.

725 **Luzio, J. P., P. R. Pryor and N. A. Bright (2007).** "Lysosomes: fusion and function." *Nat Rev Mol Cell*
726 *Biol* **8**(8): 622-632.

727 **Maeda, T. and S. Ohnishi (1980).** "Activation of influenza virus by acidic media causes hemolysis and
728 fusion of erythrocytes." *FEBS Lett* **122**(2): 283-287.

729 **Markovic, I., E. Leikina, M. Zhukovsky, J. Zimmerberg and L. V. Chernomordik (2001).** "Synchronized
730 activation and refolding of influenza hemagglutinin in multimeric fusion machines." *J Cell Biol*
731 **155**(5): 833-844.

732 **Martin, K. and A. Helenius (1991).** "Transport of Incoming Influenza Virus Nucleocapsids into the
733 Nucleus." *J. Virol.* **65**: 232-244.

734 **Martinez, O., T. Tsibane and C. F. Basler (2009).** "Neutralizing anti-influenza virus monoclonal
735 antibodies: therapeutics and tools for discovery." *Int Rev Immunol* **28**(1): 69-92.

736 **Matlin, K. S., H. Reggio, A. Helenius and K. Simons (1981).** "Infectious entry pathway of influenza
737 virus in a canine kidney cell line." *J Cell Biol* **91**(3 Pt 1): 601-613.

738 **Matrosovich, M., J. Stech and H. D. Klenk (2009).** "Influenza receptors, polymerase and host range."
739 *Rev Sci Tech* **28**(1): 203-217.

740 **Matsubara, T., A. Onishi, T. Saito, A. Shimada, H. Inoue, T. Taki, K. Nagata, Y. Okahata and T. Sato**
741 **(2010).** "Sialic acid-mimic peptides as hemagglutinin inhibitors for anti-influenza therapy." *J*
742 *Med Chem* **53**(11): 4441-4449.

743 **Matsubara, T., M. Sumi, H. Kubota, T. Taki, Y. Okahata and T. Sato (2009).** "Inhibition of influenza
744 virus infections by sialylgalactose-binding peptides selected from a phage library." *J Med*
745 *Chem* **52**(14): 4247-4256.

746 **Maxfield, F. R. and D. J. Yamashiro (1987).** "Endosome acidification and the pathways of receptor-
747 mediated endocytosis." *Adv Exp Med Biol* **225**: 189-198.

748 **Melen, K., R. Fagerlund, J. Franke, M. Kohler, L. Kinnunen and I. Julkunen (2003).** "Importin alpha
749 nuclear localization signal binding sites for STAT1, STAT2, and influenza A virus
750 nucleoprotein." *J Biol Chem* **278**(30): 28193-28200.

751 **Melikyan, G. B., W. D. Niles and F. S. Cohen (1993a).** "Influenza virus hemagglutinin-induced cell-
752 planar bilayer fusion: quantitative dissection of fusion pore kinetics into stages." *J Gen*
753 *Physiol* **102**(6): 1151-1170.

754 **Melikyan, G. B., W. D. Niles, M. E. Peeples and F. S. Cohen (1993b).** "Influenza hemagglutinin-
755 mediated fusion pores connecting cells to planar membranes: flickering to final expansion." *J*
756 *Gen Physiol* **102**(6): 1131-1149.

757 **Mellman, I. (1996).** "Endocytosis and molecular sorting." *Annu Rev Cell Dev Biol* **12**: 575-625.

758 **Mu, F. T., J. M. Callaghan, O. Steele-Mortimer, H. Stenmark, R. G. Parton, P. L. Campbell, J.**
759 **McCluskey, J. P. Yeo, E. P. Tock, et al. (1995).** "EEA1, an early endosome-associated protein.
760 EEA1 is a conserved alpha-helical peripheral membrane protein flanked by cysteine "fingers"
761 and contains a calmodulin-binding IQ motif." *J Biol Chem* **270**(22): 13503-13511.

762 **Muller, K. H., D. E. Kainov, K. El Bakkouri, X. Saelens, J. K. De Brabander, C. Kittel, E. Samm and C. P.**
763 **Muller (2011).** "The proton translocation domain of cellular vacuolar ATPase provides a
764 target for the treatment of influenza A virus infections." *Br J Pharmacol* **164**(2): 344-357.

765 **Nicholls, J. M., R. B. Moss and S. M. Haslam (2013).** "The use of sialidase therapy for respiratory viral
766 infections." *Antiviral Res* **98**(3): 401-409.

767 **Nicol, M. Q., Y. Ligertwood, M. N. Bacon, B. M. Dutia and A. A. Nash (2012).** "A novel family of
768 peptides with potent activity against influenza A viruses." *J Gen Virol* **93**(Pt 5): 980-986.

769 **Nielsen, E., F. Severin, J. M. Backer, A. A. Hyman and M. Zerial (1999).** "Rab5 regulates motility of
770 early endosomes on microtubules." *Nat Cell Biol* **1**(6): 376-382.

771 **Noton, S. L., E. Medcalf, D. Fisher, A. E. Mullin, D. Elton and P. Digard (2007).** "Identification of the
772 domains of the influenza A virus M1 matrix protein required for NP binding, oligomerization
773 and incorporation into virions." *J Gen Virol* **88**(Pt 8): 2280-2290.

774 **O'Neill, R., R. Jaskunas, G. Blobel, P. Palese and J. Moroianu (1995).** "Nuclear import of influenza
775 virus RNA can be mediated by viral nucleoprotein and transport factors required for protein
776 import." *J. Biol. Chem.* **270**: 22701-22704.

777 **Ochiai, H., S. Sakai, T. Hirabayashi, Y. Shimizu and K. Terasawa (1995).** "Inhibitory effect of
778 bafilomycin A1, a specific inhibitor of vacuolar-type proton pump, on the growth of influenza
779 A and B viruses in MDCK cells." *Antiviral Res* **27**(4): 425-430.

780 **Okada, A., T. Miura and H. Takeuchi (2003).** "Zinc- and pH-dependent conformational transition in a
781 putative interdomain linker region of the influenza virus matrix protein M1." *Biochemistry*
782 **42(7):** 1978-1984.

783 **Okuno, Y., Y. Isegawa, F. Sasao and S. Ueda (1993).** "A common neutralizing epitope conserved
784 between the hemagglutinins of influenza A virus H1 and H2 strains." *J Virol* **67(5):** 2552-2558.

785 Palese, P. and M. L. Shaw (2007). Orthomyxoviridae: The viruses and their replication. *Fields Virology*.
786 D. M. Knipe and P. M. Howley. Philadelphia, Lippincott Williams and Wilkins. **2.**

787 **Patterson, S., J. S. Oxford and R. R. Dourmashkin (1979).** "Studies on the mechanism of influenza
788 virus entry into cells." *J Gen Virol* **43(1):** 223-229.

789 **Perez, L. and L. Carrasco (1994).** "Involvement of the vacuolar H(+)-ATPase in animal virus entry." *J*
790 *Gen Virol* **75 (Pt 10):** 2595-2606.

791 **Pinto, L. H., L. J. Holsinger and R. A. Lamb (1992).** "Influenza virus M2 protein has ion channel
792 activity." *Cell* **69:** 517-528.

793 **Plotch, S. J., B. O'Hara, J. Morin, O. Palant, J. LaRocque, J. D. Bloom, S. A. Lang, Jr., M. J. DiGrandi,**
794 **M. Bradley, et al. (1999).** "Inhibition of influenza A virus replication by compounds
795 interfering with the fusogenic function of the viral hemagglutinin." *J Virol* **73(1):** 140-151.

796 **Rabinovich, S., J. T. Baldini and R. Bannister (1969).** "Treatment of influenza. The therapeutic
797 efficacy of rimantadine HC1 in a naturally occurring influenza A2 outbreak." *Am J Med Sci*
798 **257(5):** 328-335.

799 **Reading, P. C., J. L. Miller and E. M. Anders (2000).** "Involvement of the mannose receptor in
800 infection of macrophages by influenza virus." *J Virol* **74(11):** 5190-5197.

801 **Rink, J., E. Ghigo, Y. Kalaidzidis and M. Zerial (2005).** "Rab conversion as a mechanism of progression
802 from early to late endosomes." *Cell* **122(5):** 735-749.

803 **Roberts, K. L., H. Shelton, M. Scull, R. Pickles and W. S. Barclay (2011).** "Lack of transmission of a
804 human influenza virus with avian receptor specificity between ferrets is not due to decreased
805 virus shedding but rather a lower infectivity in vivo." *J Gen Virol* **92(Pt 8):** 1822-1831.

806 **Roberts, P. C., W. Garten and H. D. Klenk (1993).** "Role of Conserved Glycosylation Sites in
807 Maturation and Transport of Influenza-A Virus Hemagglutinin." *J. Virol.* **67:** 3048-3060.

808 **Roberts, P. C., R. A. Lamb and R. W. Compans (1998).** "The M1 and M2 proteins of influenza A virus
809 are important determinants in filamentous particle formation." *Virology* **240(1):** 127-137.

810 **Rossman, J. S. and R. A. Lamb (2011).** "Influenza virus assembly and budding." *Virology* **411(2):** 229-
811 236.

812 **Rossman, J. S., G. P. Leser and R. A. Lamb (2012).** "Filamentous influenza virus enters cells via
813 macropinocytosis." *J Virol* **86(20):** 10950-10960.

814 **Roy, A. M., J. S. Parker, C. R. Parrish and G. R. Whittaker (2000).** "Early stages of influenza virus
815 entry into Mv-1 lung cells: involvement of dynamin." *Virology* **267(1):** 17-28.

816 **Ruigrok, R. W., A. Barge, P. Durrer, J. Brunner, K. Ma and G. R. Whittaker (2000).** "Membrane
817 interaction of influenza virus M1 protein." *Virology* **267(2):** 289-298.

818 **Russell, R. J., P. S. Kerry, D. J. Stevens, D. A. Steinhauer, S. R. Martin, S. J. Gamblin and J. J. Skehel**
819 **(2008).** "Structure of influenza hemagglutinin in complex with an inhibitor of membrane
820 fusion." *Proc Natl Acad Sci U S A* **105(46):** 17736-17741.

821 **Rust, M. J., M. Lakadamyali, F. Zhang and X. Zhuang (2004).** "Assembly of endocytic machinery
822 around individual influenza viruses during viral entry." *Nat Struct Mol Biol* **11(6):** 567-573.

823 **Sauter, N. K., M. D. Bednarski, B. A. Wurzburg, J. E. Hanson, G. M. Whitesides, J. J. Skehel and D. C.**
824 **Wiley (1989).** "Hemagglutinins from two influenza virus variants bind to sialic acid derivatives
825 with millimolar dissociation constants: a 500-MHz proton nuclear magnetic resonance
826 study." *Biochemistry* **28(21):** 8388-8396.

827 **Schmitt, A. P. and R. A. Lamb (2005).** "Influenza virus assembly and budding at the viral budzone."
828 *Adv Virus Res* **64:** 383-416.

829 **Sieczkarski, S. B., H. A. Brown and G. R. Whittaker (2003).** "Role of protein kinase C beta11 in
830 influenza virus entry via late endosomes." *J Virol* **77(1):** 460-469.

831 **Sieczkarski, S. B. and G. R. Whittaker (2002).** "Influenza virus can enter and infect cells in the
832 absence of clathrin-mediated endocytosis." *J Virol* **76**(20): 10455-10464.

833 **Sieczkarski, S. B. and G. R. Whittaker (2003).** "Differential requirements of Rab5 and Rab7 for
834 endocytosis of influenza and other enveloped viruses." *Traffic* **4**(5): 333-343.

835 **Sieczkarski, S. B. and G. R. Whittaker (2005).** "Characterization of the host cell entry of filamentous
836 influenza virus." *Arch Virol* **150**(9): 1783-1796.

837 **Simonsen, A., R. Lippe, S. Christoforidis, J. M. Gaullier, A. Brech, J. Callaghan, B. H. Toh, C. Murphy,
838 M. Zerial, et al. (1998).** "EEA1 links PI(3)K function to Rab5 regulation of endosome fusion."
839 *Nature* **394**(6692): 494-498.

840 **Skehel, J. J., A. J. Hay and J. A. Armstrong (1978).** "On the mechanism of inhibition of influenza virus
841 replication by amantadine hydrochloride." *J Gen Virol* **38**(1): 97-110.

842 **Skehel, J. J. and D. C. Wiley (2000).** "Receptor binding and membrane fusion in virus entry: the
843 influenza hemagglutinin." *Annu Rev Biochem* **69**: 531-569.

844 **Spruce, A. E., A. Iwata, J. M. White and W. Almers (1989).** "Patch clamp studies of single cell-fusion
845 events mediated by a viral fusion protein." *Nature* **342**(6249): 555-558.

846 **Steinhauer, D. A. (2013).** "Influenza: Pathways to human adaptation." *Nature* **499**(7459): 412-413.

847 **Steinman, R. M., I. S. Mellman, W. A. Muller and Z. A. Cohn (1983).** "Endocytosis and the recycling
848 of plasma membrane." *J Cell Biol* **96**(1): 1-27.

849 **Stevens, J., O. Blixt, L. Glaser, J. K. Taubenberger, P. Palese, J. C. Paulson and I. A. Wilson (2006a).**
850 "Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza
851 viruses reveals different receptor specificities." *J Mol Biol* **355**(5): 1143-1155.

852 **Stevens, J., O. Blixt, T. M. Tumpey, J. K. Taubenberger, J. C. Paulson and I. A. Wilson (2006b).**
853 "Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus."
854 *Science* **312**(5772): 404-410.

855 **Stouffer, A. L., R. Acharya, D. Salom, A. S. Levine, L. Di Costanzo, C. S. Soto, V. Tereshko, V. Nanda,
856 S. Stayrook, et al. (2008).** "Structural basis for the function and inhibition of an influenza
857 virus proton channel." *Nature* **451**(7178): 596-599.

858 **Stray, S. J., R. D. Cummings and G. M. Air (2000).** "Influenza virus infection of desialylated cells."
859 *Glycobiology* **10**(7): 649-658.

860 **Su, W. C., Y. C. Chen, C. H. Tseng, P. W. Hsu, K. F. Tung, K. S. Jeng and M. M. Lai (2013).** "Pooled
861 RNAi screen identifies ubiquitin ligase Itch as crucial for influenza A virus release from the
862 endosome during virus entry." *Proc Natl Acad Sci U S A* **110**(43): 17516-17521.

863 **Sugrue, R. J. and A. J. Hay (1991).** "Structural characteristics of the M2 protein of influenza A viruses:
864 evidence that it forms a tetrameric channel." *Virology* **180**: 617-624.

865 **Sui, J., W. C. Hwang, S. Perez, G. Wei, D. Aird, L. M. Chen, E. Santelli, B. Stec, G. Cadwell, et al.
866 (2009).** "Structural and functional bases for broad-spectrum neutralization of avian and
867 human influenza A viruses." *Nat Struct Mol Biol* **16**(3): 265-273.

868 **Sun, X., Y. Shi, X. Lu, J. He, F. Gao, J. Yan, J. Qi and G. F. Gao (2013).** "Bat-derived influenza
869 hemagglutinin H17 does not bind canonical avian or human receptors and most likely uses a
870 unique entry mechanism." *Cell Rep* **3**(3): 769-778.

871 **Sun, X. and G. R. Whittaker (2007).** "Role of the actin cytoskeleton during influenza virus
872 internalization into polarized epithelial cells." *Cell Microbiol* **9**(7): 1672-1682.

873 **Sweet, C., F. G. Hayden, K. J. Jakeman, S. Grambas and A. J. Hay (1991).** "Virulence of rimantadine-
874 resistant human influenza A (H3N2) viruses in ferrets." *J Infect Dis* **164**(5): 969-972.

875 **Tatulian, S. A., P. Hinterdorfer, G. Baber and L. K. Tamm (1995).** "Influenza hemagglutinin assumes a
876 tilted conformation during membrane fusion as determined by attenuated total reflection
877 FTIR spectroscopy." *Embo J* **14**(22): 5514-5523.

878 **Terabayashi, T., M. Morita, M. Ueno, T. Nakamura and T. Urashima (2006).** "Inhibition of influenza-
879 virus-induced cytopathy by sialylglycoconjugates." *Carbohydr Res* **341**(13): 2246-2253.

880 **Thompson, C. I., W. S. Barclay, M. C. Zambon and R. J. Pickles (2006).** "Infection of human airway
881 epithelium by human and avian strains of influenza a virus." *J Virol* **80**(16): 8060-8068.

882 **Throsby, M., E. van den Brink, M. Jongeneelen, L. L. Poon, P. Alard, L. Cornelissen, A. Bakker, F.**
883 **Cox, E. van Deventer, et al. (2008).** "Heterosubtypic neutralizing monoclonal antibodies
884 cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells." *PLoS*
885 *One* **3**(12): e3942.

886 **Tong, S., Y. Li, P. Rivaller, C. Conrardy, D. A. Castillo, L. M. Chen, S. Recuenco, J. A. Ellison, C. T.**
887 **Davis, et al. (2012).** "A distinct lineage of influenza A virus from bats." *Proc Natl Acad Sci U S*
888 *A* **109**(11): 4269-4274.

889 **Tong, S., X. Zhu, Y. Li, M. Shi, J. Zhang, M. Bourgeois, H. Yang, X. Chen, S. Recuenco, et al. (2013).**
890 "New world bats harbor diverse influenza A viruses." *PLoS Pathog* **9**(10): e1003657.

891 **Tsurudome, M., R. Gluck, R. Graf, R. Falchetto, U. Schaller and J. Brunner (1992).** "Lipid interactions
892 of the hemagglutinin HA2 NH2-terminal segment during influenza virus-induced membrane
893 fusion." *J Biol Chem* **267**(28): 20225-20232.

894 **Upham, J. P., D. Pickett, T. Irimura, E. M. Anders and P. C. Reading (2010).** "Macrophage receptors
895 for influenza A virus: role of the macrophage galactose-type lectin and mannose receptor in
896 viral entry." *J Virol* **84**(8): 3730-3737.

897 **Vanderlinden, E., F. Goktas, Z. Cesur, M. Froeyen, M. L. Reed, C. J. Russell, N. Cesur and L. Naesens**
898 **(2010).** "Novel inhibitors of influenza virus fusion: structure-activity relationship and
899 interaction with the viral hemagglutinin." *J Virol* **84**(9): 4277-4288.

900 **Vanderlinden, E. and L. Naesens (2013).** "Emerging Antiviral Strategies to Interfere with Influenza
901 Virus Entry." *Med Res Rev*.

902 **Vigant, F., J. Lee, A. Hollmann, L. B. Tanner, Z. Akyol Ataman, T. Yun, G. Shui, H. C. Aguilar, D.**
903 **Zhang, et al. (2013).** "A mechanistic paradigm for broad-spectrum antivirals that target virus-
904 cell fusion." *PLoS Pathog* **9**(4): e1003297.

905 **Wang, C., K. Takeuchi, L. H. Pinto and R. A. Lamb (1993).** "Ion channel activity of influenza A virus
906 M2 protein: characterization of the amantadine block." *J Virol* **67**(9): 5585-5594.

907 **Wang, J., C. Ma, H. Jo, B. Canturk, G. Fiorin, L. H. Pinto, R. A. Lamb, M. L. Klein and W. F. DeGrado**
908 **(2013).** "Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-
909 resistant mutant, S31N, of the M2 proton channel from influenza A virus." *J Med Chem* **56**(7):
910 2804-2812.

911 **Wang, P., P. Palese and R. E. O'Neill (1997).** "The NPI-1/NPI-3 (Karyopherin alpha) binding site on the
912 influenza A virus nucleoprotein NP is a nonconventional nuclear localization signal." *J. Virol.*
913 **71**: 1850-1856.

914 **Wang, S. F., J. C. Huang, Y. M. Lee, S. J. Liu, Y. J. Chan, Y. P. Chau, P. Chong and Y. M. Chen (2008).**
915 "DC-SIGN mediates avian H5N1 influenza virus infection in cis and in trans." *Biochem Biophys*
916 *Res Commun* **373**(4): 561-566.

917 **Weber, F., G. Kochs, S. Gruber and O. Haller (1998).** "A classical bipartite nuclear localization signal
918 on the Thogoto and influenza A virus nucleoproteins." *Virology* **250**: 9-18.

919 **Weber, T., G. Paesold, C. Galli, R. Mischler, G. Semenza and J. Brunner (1994).** "Evidence for H(+)-
920 induced insertion of influenza hemagglutinin HA2 N-terminal segment into viral membrane."
921 *J Biol Chem* **269**(28): 18353-18358.

922 **Weis, W., J. H. Brown, S. Cusack, J. C. Paulson, J. J. Skehel and D. C. Wiley (1988).** "Structure of the
923 influenza virus haemagglutinin complexed with its receptor, sialic acid." *Nature* **333**(6172):
924 426-431.

925 **Wharton, S. A., R. B. Belshe, J. J. Skehel and A. J. Hay (1994).** "Role of virion M2 protein in influenza
926 virus uncoating: specific reduction in the rate of membrane fusion between virus and
927 liposomes by amantadine." *J Gen Virol* **75 (Pt 4)**: 945-948.

928 **White, J. M. and I. A. Wilson (1987).** "Anti-peptide antibodies detect steps in a protein
929 conformational change: low-pH activation of the influenza virus hemagglutinin." *J Cell Biol*
930 **105**(6 Pt 2): 2887-2896.

931 **Whittle, J. R., R. Zhang, S. Khurana, L. R. King, J. Manischewitz, H. Golding, P. R. Dormitzer, B. F.**
932 **Haynes, E. B. Walter, et al. (2011).** "Broadly neutralizing human antibody that recognizes the

933 receptor-binding pocket of influenza virus hemagglutinin." *Proc Natl Acad Sci U S A* **108**(34):
934 14216-14221.

935 **Wilks, S., M. de Graaf, D. J. Smith and D. F. Burke (2012)**. "A review of influenza haemagglutinin
936 receptor binding as it relates to pandemic properties." *Vaccine* **30**(29): 4369-4376.

937 **Wolf, M. C., A. N. Freiberg, T. Zhang, Z. Akyol-Ataman, A. Grock, P. W. Hong, J. Li, N. F. Watson, A.**
938 **Q. Fang, et al. (2010)**. "A broad-spectrum antiviral targeting entry of enveloped viruses."
939 *Proc Natl Acad Sci U S A* **107**(7): 3157-3162.

940 **Xiong, X., P. J. Coombs, S. R. Martin, J. Liu, H. Xiao, J. W. McCauley, K. Locher, P. A. Walker, P. J.**
941 **Collins, et al. (2013a)**. "Receptor binding by a ferret-transmissible H5 avian influenza virus."
942 *Nature* **497**(7449): 392-396.

943 **Xiong, X., S. R. Martin, L. F. Haire, S. A. Wharton, R. S. Daniels, M. S. Bennett, J. W. McCauley, P. J.**
944 **Collins, P. A. Walker, et al. (2013b)**. "Receptor binding by an H7N9 influenza virus from
945 humans." *Nature* **499**(7459): 496-499.

946 **Xu, R., R. McBride, J. C. Paulson, C. F. Basler and I. A. Wilson (2010)**. "Structure, receptor binding,
947 and antigenicity of influenza virus hemagglutinins from the 1957 H2N2 pandemic." *J Virol*
948 **84**(4): 1715-1721.

949 **Yamauchi, Y., H. Boukari, I. Banerjee, I. F. Sbalzarini, P. Horvath and A. Helenius (2011)**. "Histone
950 deacetylase 8 is required for centrosome cohesion and influenza A virus entry." *PLoS Pathog*
951 **7**(10): e1002316.

952 **Yoshida, R., M. Igarashi, H. Ozaki, N. Kishida, D. Tomabechi, H. Kida, K. Ito and A. Takada (2009)**.
953 "Cross-protective potential of a novel monoclonal antibody directed against antigenic site B
954 of the hemagglutinin of influenza A viruses." *PLoS Pathog* **5**(3): e1000350.

955 **Yoshimoto, J., M. Kakui, H. Iwasaki, T. Fujiwara, H. Sugimoto and N. Hattori (1999)**. "Identification
956 of a novel HA conformational change inhibitor of human influenza virus." *Arch Virol* **144**(5):
957 865-878.

958 **Yoshimura, A., K. Kuroda, K. Kawasaki, S. Yamashina, T. Maeda and S. Ohnishi (1982)**. "Infectious
959 cell entry mechanism of influenza virus." *J Virol* **43**(1): 284-293.

960 **Zebedee, S. L. and R. A. Lamb (1988)**. "Influenza A virus M2 protein: monoclonal antibody restriction
961 of virus growth and detection of M2 in virions." *J Virol* **62**(8): 2762-2772.

962 **Zerial, M. and H. McBride (2001)**. "Rab proteins as membrane organizers." *Nat Rev Mol Cell Biol* **2**(2):
963 107-117.

964 **Zhang, J. and R. A. Lamb (1996)**. "Characterization of the membrane association of the influenza
965 virus matrix protein in living cells." *Virology* **225**(2): 255-266.

966 **Zhirnov, O. P. (1990)**. "Solubilization of matrix protein M1/M from virions occurs at different pH for
967 orthomyxo- and paramyxoviruses." *Virology* **176**(1): 274-279.

968 **Zhu, L., Y. Li, S. Li, H. Li, Z. Qiu, C. Lee, H. Lu, X. Lin, R. Zhao, et al. (2011)**. "Inhibition of influenza A
969 virus (H1N1) fusion by benzenesulfonamide derivatives targeting viral hemagglutinin." *PLoS*
970 *One* **6**(12): e29120.

971 **Zhu, L., H. Ly and Y. Liang (2013a)**. "PLC-gamma1 signaling plays a subtype-specific role in post-
972 binding cell entry of Influenza A virus." *J Virol*.

973 **Zhu, X., W. Yu, R. McBride, Y. Li, L. M. Chen, R. O. Donis, S. Tong, J. C. Paulson and I. A. Wilson**
974 **(2013b)**. "Hemagglutinin homologue from H17N10 bat influenza virus exhibits divergent
975 receptor-binding and pH-dependent fusion activities." *Proc Natl Acad Sci U S A* **110**(4): 1458-
976 1463.

977

978 **Figure legends**

979 **Fig. 1: Schematic representation of the influenza A virus entry process.**

980 **Fig. 2: Structure of hemagglutinin**

981 a) Structure of the hemagglutinin of influenza A virus A/SouthCarolina/1918 based on
982 (Gamblin et al. 2004; PDB accession no. 1RUZ). The trimeric complex of HA is
983 shown with one monomer highlighted in colour. HA1 is depicted in red, HA2 in blue
984 and the receptor binding site in green.

985 b) The pre- and post fusion conformations of HA are shown (Bullough et al. 1994;
986 PDB accession no. 1HTM). For the post fusion conformation only the structure of the
987 part represented in blue could be resolved. HA1 was not included in the structure and
988 was modelled on according to (Palese and Shaw 2007).

989 **Fig. 3: Super resolution microscopy of influenza A virus in endosomes**

990 A549 lung epithelial cells were infected with influenza A virus (A/WSN/33, MOI of 25)
991 for 30-180 minutes. Virus was added to the cells in an initial cold binding step to
992 synchronize the infection process. Cells were fixed and stained for DAPI and NP (a),
993 DAPI, NP and EEA1 (b1) or NP and EEA1 (b2-b4). Images were acquired by
994 standard immunofluorescence microscopy (CLSM – confocal laser scanning
995 microscopy, a, b1) or super resolution microscopy (STED – stimulated emission
996 depletion, b2-b4). In b3-b4 rendered (IMARIS) images of viral particles within
997 endosomes are shown. In b4 the transparency of the endosomal staining was
998 increased to allow visibility of viral particles inside the respective endosome.

Table 1: Host factors involved in IAV entry

host factor	entry step	reference
sialic acid	attachment	Palese and Shaw, 2007
C-type lectins	attachment	reviewed by Londrigan <i>et al.</i> , 2011
annexin V	attachment	Huang <i>et al.</i> , 1996
6-sulfo sialyl Lewis X	attachment	Gambaryan <i>et al.</i> , 2008
dynamin	internalization	Roy <i>et al.</i> , 2000(Roy <i>et al.</i> 2000)
actin	internalization	Gottlieb <i>et al.</i> , 1993(Gottlieb <i>et al.</i> 1993)
clathrin	internalization	Matlin <i>et al.</i> , 1981
epsin-1	internalization	Chen <i>et al.</i> , 2008
EGFR	internalization	Eierhoff <i>et al.</i> , 2010
c-Met kinase	internalization	Eierhoff <i>et al.</i> , 2010
PLC-γ1	internalization	Zhu <i>et al.</i> , 2013
Rab 5	endosomal trafficking	Sieczkarski <i>et al.</i> , 2003
Rab7	endosomal trafficking	Sieczkarski <i>et al.</i> , 2003
PKC βII	endosomal trafficking	Sieczkarski <i>et al.</i> , 2003
cullin 3	endosomal trafficking	Huotari <i>et al.</i> , 2012
HDAC8	endosomal trafficking	Yamauchi <i>et al.</i> , 2011
vATPase	endosomal acidification	Guinea <i>et al.</i> , 1995(Guinea and Carrasco 1995)
CD81	fusion	He <i>et al.</i> , 2013
ITCH	uncoating	Su <i>et al.</i> , 2013
karyopherin (α1; α3; α5)	import	Wang <i>et al.</i> , 1997
Ran	import	O'Neill <i>et al.</i> , 1995
p10	import	O'Neill <i>et al.</i> , 1995
CSE1L	import	Konig <i>et al.</i> , 2010

Table 2: Inhibitors of IAV entry

inhibitor	entry step	potential as drug	reference
mAbs (HA-RBP)	attachment	yes	reviewed by Clementi <i>et al.</i> , 2012 (Clementi et al. 2012)
SA mimics	attachment	yes	reviewed by Vanderlinden <i>et al.</i> , 2013 (Vanderlinden and Naesens 2013)
SA binders	attachment	yes	reviewed by Vanderlinden <i>et al.</i> , 2013
Sialidases e.g. DAS181	attachment	yes/phase II trial	reviewed by Nicholls <i>et al.</i> , 2013
Dynasore	internalization	laboratory use	De Vries <i>et al.</i> , 2011
EIPA	internalization	laboratory use	De Vries <i>et al.</i> , 2011
Receptor tyrosine kinase inhibitors	internalization		Eierhoff <i>et al.</i> , 2010 and De Vries <i>et al.</i> , 2012
Lj001	internalization	yes	Wolf <i>et al.</i> , 2010
Bafilomycin A1	endosomal acidification	laboratory use	Guinea <i>et al.</i> , 1995
mAbs (HA stalk)	fusion	yes	reviewed by Corti <i>et al.</i> , 2013 (Corti and Lanzavecchia 2013)
Small molecule inhibitors (HA stalk)	fusion	yes	reviewed by Vanderlinden <i>et al.</i> , 2013
Amantadine	uncoating	approved	Davies <i>et al.</i> , 1964
Rimantadine	uncoating	approved	Rabinovich <i>et al.</i> , 1969 (Rabinovich et al. 1969)
benzyl-substituted amantadine derivatives	uncoating	yes	Wang <i>et al.</i> , 2013
importazole	import	laboratory use	Chou <i>et al.</i> , 2013 (Chou et al. 2013)

Influenza A Virus






Figure 2: Kinetics of IAV entry



A549 lung epithelial cells were infected with Influenza A virus (A/WSN/33, MOI of 25) for 30-180 minutes. Virus was added to the cells in an initial cold binding step to synchronize the infection process. Cells were fixed at the indicated times p.i. and immunofluorescence microscopy was carried out for NP and DAPI signal. Scale-bar equals 10 μ m.

Figure 3: Super resolution microscopy of influenza A virus in endosomes



A549 lung epithelial cells were infected with influenza A virus (A/WSN/33, MOI of 25) for 60 minutes. Virus was added to the cells in an initial cold binding step to synchronize the infection process. Cells were fixed and (A) standard immunofluorescence microscopy (CLSM – confocal laser scanning microscope) for DAPI, NP and EEA1 signal or (B-D) super resolution microscopy (STED – stimulated emission depletion) for NP and EEA1 was carried out. In C/D rendered (IMARIS) images of viral particles within endosomes are shown. In D the transparency of the endosomal staining was increased to allow visibility of viral particles inside the respective endosome.